NASDAQ:PAVM PAVmed (PAVM) Stock Price, News & Analysis $1.01 -0.03 (-2.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.01▼$1.0650-Day Range$0.71▼$1.8452-Week Range$0.60▼$9.00Volume227,717 shsAverage Volume66,783 shsMarket Capitalization$9.52 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get PAVmed alerts: Email Address PAVmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,979.2% Upside$21.00 Price TargetShort InterestBearish3.19% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.68 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPAVmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePAVmed has only been the subject of 1 research reports in the past 90 days.Read more about PAVmed's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.19% of the float of PAVmed has been sold short.Short Interest Ratio / Days to CoverPAVmed has a short interest ratio ("days to cover") of 4.1.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldPAVmed does not currently pay a dividend.Dividend GrowthPAVmed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePAVmed has received a 63.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Medical devices engineering", "Intravenous therapy equipment", and "Biopsy systems" products. See details.Environmental SustainabilityThe Environmental Impact score for PAVmed is -0.78. Previous Next 2.7 News and Social Media Coverage News SentimentPAVmed has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PAVmed this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PAVmed insiders have not sold or bought any company stock.Percentage Held by Insiders12.60% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.93% of the stock of PAVmed is held by institutions.Read more about PAVmed's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of PAVmed is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PAVmed is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PAVmed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About PAVmed Stock (NASDAQ:PAVM)PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More PAVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PAVM Stock News HeadlinesJuly 23 at 8:01 AM | prnewswire.comLucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeJuly 18, 2024 | americanbankingnews.comPAVmed (NASDAQ:PAVM) Shares Pass Below 50 Day Moving Average of $1.23July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 11, 2024 | prnewswire.comLucid Diagnostics Launches New Corporate WebsiteJuly 2, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationJune 13, 2024 | prnewswire.comPAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteJune 12, 2024 | prnewswire.com4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer TestingMay 18, 2024 | finanznachrichten.dePAVmed Inc.: PAVmed Provides Business Update and First Quarter 2024 Financial ResultsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | finance.yahoo.comPAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...May 13, 2024 | prnewswire.comPAVmed Provides Business Update and First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comLegacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA RecallMay 7, 2024 | prnewswire.comLucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of DirectorsMay 3, 2024 | prnewswire.comPAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024May 2, 2024 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024May 2, 2024 | prnewswire.comLucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingMay 1, 2024 | finance.yahoo.comVeris teams up with Ohio University for cancer digital health pilotApril 30, 2024 | prnewswire.comPAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstituteSee More Headlines Receive PAVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:PAVM CUSIPN/A CIK1624326 Webwww.pavmed.com Phone(212) 949-4319FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,979.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($9.0978) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,180,000.00 Net Margins-2,037.67% Pretax Margin-2,505.34% Return on EquityN/A Return on Assets-99.19% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.53 Sales & Book Value Annual Sales$2.45 million Price / Sales3.89 Cash FlowN/A Price / Cash FlowN/A Book Value($3.35) per share Price / Book-0.30Miscellaneous Outstanding Shares9,430,000Free Float8,244,000Market Cap$9.52 million OptionableOptionable Beta0.65 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Lishan Aklog M.D. (Age 58)Chairman & CEO Comp: $953.2kMr. Dennis M. McGrath CPA (Age 67)President & CFO Comp: $673.5kMr. Shaun M. O'Neill M.B.A. (Age 41)Executive VP & COO Comp: $498kMr. Michael Adam Gordon (Age 49)Executive VP, General Counsel & Secretary Comp: $710.5kDr. Brian J. deGuzman M.D. (Age 59)Executive VP, Chief Technology & Compliance Officer Comp: $427.6kDr. Suman M. Verma M.D.Ph.D., Senior VP of Molecular Genetics & Chief Scientific OfficerMichael ParksVice President of Investor RelationsDr. Deepika A. Lakhani Ph.D.Senior VP, Chief Regulatory & Quality OfficerDr. Victoria T. Lee M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsIceCure MedicalNASDAQ:ICCMDarioHealthNASDAQ:DRIOiCADNASDAQ:ICADAkiliNASDAQ:AKLIRetractable TechnologiesNYSE:RVPView All Competitors PAVM Stock Analysis - Frequently Asked Questions How have PAVM shares performed this year? PAVmed's stock was trading at $4.12 at the beginning of 2024. Since then, PAVM shares have decreased by 75.5% and is now trading at $1.01. View the best growth stocks for 2024 here. How were PAVmed's earnings last quarter? PAVmed Inc. (NASDAQ:PAVM) posted its earnings results on Monday, May, 13th. The company reported ($0.99) EPS for the quarter. The business had revenue of $1.01 million for the quarter. When did PAVmed's stock split? PAVmed's stock reverse split before market open on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of PAVmed? Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PAVmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Co-Diagnostics (CODX), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Cidara Therapeutics (CDTX). This page (NASDAQ:PAVM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
